Miltenyi Biotec’s Global T-Cell Manufacturing Platform Integrates Automated Closed Systems, Cuts Manual Labor by Over 70%, Achieves High Yields

June 20, 2026

Bioprocess Online Germany

Overview

Miltenyi Biotec proposes that global scaling of TCR-T cell manufacturing requires a fundamental process redesign, integrating six key production steps into a single automated, closed system. This integrated approach can reduce manual labor by over 70% and enable reliable batch production with high yields exceeding 1.5 × 10¹⁰ viable cells. This represents a critical breakthrough for the commercialization of cell therapies and improving global patient access, aiming to overcome challenges in manufacturing costs and quality control.

In Depth

Key Findings

Miltenyi Biotec has proposed that a fundamental redesign of the process is essential to enable global scaling of TCR-T cell (T-cell receptor gene-modified T cell) manufacturing. The company has established a solution that integrates six key production steps into a single automated, closed system, achieving a reduction in manual labor by over 70% and reliable batch production with high yields of over 1.5 × 10¹⁰ viable cells.

Technical / Clinical Details

Integrated Automated Platform: Miltenyi Biotec’s approach is characterized by performing a series of processes—including cell collection, activation, gene transduction, expansion, washing, and cryopreservation—within a fully closed and automated system. This minimizes contamination risks and maximizes process reproducibility and consistency.
Significant Reduction in Manual Labor: Traditional T-cell manufacturing processes are heavily reliant on manual operations, leading to risks of human error, high costs, and variability in reproducibility. This automated closed system overcomes these challenges by reducing manual labor by over 70%, dramatically improving manufacturing efficiency.
High Yield and Quality: The integrated platform has the capability to produce TCR-T cells with very high yields, exceeding 1.5 × 10¹⁰ viable cells. This is crucial for ensuring the large number of cells required for therapy from a small amount of starting material. Furthermore, the closed system ensures product quality and safety.
Modularity and Scalability: The system employs a modular design, allowing for easy scale-up or scale-out to meet the needs of various clinical trial stages and production scales. This enables flexible adaptation to global supply chains and regional manufacturing requirements.

Background & Context

TCR-T cell therapy, alongside CAR-T therapy, represents a promising approach in cancer immunotherapy, targeting specific tumor antigens. However, TCR-T cell manufacturing is as complex as CAR-T therapy, and establishing scalable and cost-effective manufacturing platforms to support global clinical trials and commercialization has been an urgent challenge. Companies like Miltenyi Biotec are focusing on automation and process integration to resolve this bottleneck.

Strategic Significance & Outlook

The global T-cell manufacturing platform proposed by Miltenyi Biotec, based on automated closed systems, is expected to significantly accelerate the commercialization of TCR-T cell therapies and other cell therapies. The substantial reduction in manual labor and the achievement of high yields will contribute to lower manufacturing costs and improved patient access. This will enable innovative cell therapies to be delivered quickly and safely to more patients worldwide, potentially transforming the future of cancer treatment.

Source: https://www.bioprocessonline.com/doc/building-a-scalable-global-t-cell-manufacturing-platform-0001

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.